P822: A PHASE 1 SINGLE ASCENDING DOSE STUDY OF CAN106, A LONG-ACTING ANTI-C5 COMPLEMENT MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR PNH AND OTHER COMPLEMENT-MEDIATED DISEASES

• C. M. KHOO,
• X. SONG,
• Q. WU,
• G. F. COX

Affiliations

C. M. KHOO

1 Department of Medicine, National University Hospital, Singapore, Singapore

X. SONG

2 Clinical Development and Medical Affair, CANbridge Pharmaceuticals Inc., Shanghai, China

Q. WU

2 Clinical Development and Medical Affair, CANbridge Pharmaceuticals Inc., Shanghai, China

G. F. COX

3 Clinical Development and Medical Affair, CANbridge Pharmaceuticals Inc., Cambridge, MA, United States of America